Synthetic Biologics doses first patient in SYN-004 Phase 1b trial for prevention of C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.



from The Medical News http://www.news-medical.net/news/20141231/Synthetic-Biologics-doses-first-patient-in-SYN-004-Phase-1b-trial-for-prevention-of-C-difficile-infection.aspx